An overview of the efficacy of these 4 BTK inhibitors from clinical trials (phase 1/2/3) of Chinese patients with R/R CLL/SLL is shown in Online Resource 6 [19–21]. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.